Episode 121 - November 15, 2024
On this episode, Brad Loncar, Sam Fazeli, Tess Cameron, Nina Kjellson and Michal Preminger kick off the show sharing perspectives on Trump’s selection of Robert F. Kennedy Jr as secretary of the U.S. Department of Health and Human Services. The hosts shift to Abbvie’s disappointing Phase 2 trials and a broader discussion on why M&A can be tough. The group also discussed the recent flood of licensing and new companies based on China assets, including some of the players and approaches. The hosts also discuss Halozyme's takeover proposal of Evotec, the VEGF/PD-1 frenzy, J&J hits back with 340b lawsuit, the GOP tax bill and impact on biopharma priorities, and more. This episode aired on November 15, 2024.
More description
On this episode, Brad Loncar, Sam Fazeli, Tess Cameron, Nina Kjellson and Michal Preminger kick off the show sharing perspectives on Trump’s selection of Robert F. Kennedy Jr as secretary of the U.S. Department of Health and Human Services. The hosts shift to Abbvie’s disappointing Phase 2 trials and a broader discussion on why M&A can be tough. The group also discussed the recent flood of licensing and new companies based on China assets, including some of the players and approaches. The hosts also discuss Halozyme's takeover proposal of Evotec, the VEGF/PD-1 frenzy, J&J hits back with 340b lawsuit, the GOP tax bill and impact on biopharma priorities, and more. This episode aired on November 15, 2024.
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.